Professor
M.B,. ChB 1969 , M.D, FCPSA, AGAF
Department : |
Gastroenterology
|
Room : |
|
Phone : |
|
Email : |
odes@bgu.ac.il |
Office Hours : |
|
bowel disease, health economics, epidemiology, cancer, biological therapy |
|
|
- M.D. 1969 University of Cape Town, South Africa
- Inflammatory bowel disease
- health care quality
- organization and outcomes
- health economics
- epidemiology
- Creation of a multinational cohort of patients with inflamamtory bowel diseases for clinical, genetic and economic analysis.
- Longterm follow up of patients with inflamamtory bowel diseases for defining disease outcomes.
- Health cost analysis of patients with inflammatory bowel diseases
- Patient-reported utilization of health care resources in ulcerative colitis and Crohn's disease matches their health care costs.
- Digestive Diseases Week, San Diego CA, USA, May 2008; Gastroenterology: 134, A-199, 2008.
- IBD patients need in health quality of care - ECCO Consensus. Journal of Crohn’s & Colitis, 2008; 2 (Suppl); 68-9 (abstract P216).
- Behavior and location phenotypes but not patient age drive health care costs in Crohn’s disease. A European collaborative study based on the Montreal classification. Digestive Diseases Week, Washington DC , USA , May 2007; Gastroenterology: 132, A-658, 2007.
- Refractory Ulcerative Colitis: The Conservative Approach. Falk Symposium 159. IBD 2007 – Achievements in research and clinical practice.
- Epidemiology and clinical courses of inflammatory bowel diseases
- Cancer
- Health economics of disease iv. Cost-effectiveness of biological therapies
Major expertise and techniques in the lab
- Cohort analysis
- Cost analysis
Publications and funding summary / representative publications and grants
- Odes S , Vardi H, Friger M, Esser D, Wolters F, Moum B, Waters H, Elkjaer M, Bernklev T, Tsianos E, O’Morain C, Stockbrugger R, Munkholm P, Langholz E. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. Alimentary Pharmacology and Therapeutics. 31: 735-44, 2010.
Odes S . How expensive is inflammatory bowel disease? World Journal of Gastroenterology. 14: 6641-6647, 2008. Saidel-Odes L, Borer A, Odes S . Clostridium difficile infection in patients with inflammatory bowel disease. Annals of Gastroenterology. 24: 263-270, 2011. iv. Katsanos KH, Tatsioni A, Pedersen N, Shuhaibar M, Ramore VH, Politi P, Rombrechts E, Pierek M, Clofent J, Beltrami M, Bodini J, Mouzas I, Fornaciari G, Moum B, Lakatos PL, Vermeire S, Langholz E, Odes S , O’Morain C, Stockbrugger R, Munkholm P, Tsianos EV. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European collaborative follow-up study. Journal of Crohn’s and Colitis. 5: 430-442, 2011. - Dan Greenberg – health economics
- Michael Friger – statistics
- Iris Dotan (TAU) – inflammatory bowel disease
- Pia Munkholm (University of Copenhagen) – inflammatory bowel disease
Suggested multi-disciplinary research project / research focus topics
- Epidemiology of inflammatory bowel disease across Europe and the far East
- Environmental and genetic causes of inflammatory bowel disease
- Health-cost analysis of inflammatory bowel disease